Evidence map›Paper›PMID 40910259›Full record

ReviewInternational journal of molecular medicine2025

Innovative strategies to enhance MSCs efficacy in acute kidney injury (Review).

Yuanxia Zou, Jian Dai, Jingyuan Fu, Honglian Wang, Meng Yang, Jiraporn Kantapan, Li Wang, Nathupakorn Dechsupa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuanxia Zou *Research Center for Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Jian Dai *Department of Neurology, The Third People's Hospital of Luzhou, Luzhou, Sichuan 646000, P.R. China.
Jingyuan Fu *Department of Neonatal Intensive Care Unit, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China.
Honglian WangResearch Center for Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Meng YangDepartment of Children's Diagnosis and Treatment Center, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Jiraporn KantapanMolecular Imaging and Therapy Research Unit, Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50000, Thailand.
Li WangResearch Center for Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Nathupakorn DechsupaMolecular Imaging and Therapy Research Unit, Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50000, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) remains a significant clinical challenge, characterized by rapid kidney dysfunction with potential progression to chronic kidney disease. Mesenchymal stem cells (MSCs) offer promising therapeutic potential due to their regenerative, immunomodulatory and anti‑inflammatory capabilities. Despite these advantages, clinical translation is hampered by low MSCs retention, limited cell survival and suboptimal secretion of therapeutic factors in injured renal tissues. Recent research efforts have introduced innovative strategies to optimize MSCs effectiveness, including various preconditioning approaches (hypoxia, chemical/drug‑based and biological cytokines), advanced three‑dimensional cell culture methods (hydrogels and spheroids), genetic modification techniques and improved delivery routes. The present review summarizes current advancements, underlying mechanisms and therapeutic outcomes associated with these novel strategies to enhance MSCs efficacy in AKI, highlighting their clinical potential and guiding future translational research directions.

Indexed as

Acute Kidney InjuryMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCell Culture TechniquesHumans3D cultureacute kidney injurymesenchymal stem cellsmitochondrial transferpreconditioning

Identifiers

PMID40910259
PMCPMC12425341

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.